期刊
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
卷 15, 期 -, 页码 S167-S169出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2015.02.010
关键词
AKT; cancer stem cell; Cirmtuzumab; CLL; Wnt receptor
资金
- Leukemia Lymphoma Society [SCOR 7005-14]
- National Institutes of Health grant for the CLL Research Consortium [P01-CA081534]
- California Institute of Regenerative Medicine [DR3-06924]
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL. (C) 2015 The Authors. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据